ENDRA Life Sciences (NDRA) Gains from Investment Securities (2019 - 2021)
Historic Gains from Investment Securities for ENDRA Life Sciences (NDRA) over the last 3 years, with Q3 2021 value amounting to $3.6 million.
- ENDRA Life Sciences' Gains from Investment Securities rose 88038.44% to $3.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $3.6 million, marking a year-over-year increase of 603990.88%. This contributed to the annual value of $505816.0 for FY2022, which is N/A changed from last year.
- ENDRA Life Sciences' Gains from Investment Securities amounted to $3.6 million in Q3 2021, which was up 88038.44% from $331520.0 recorded in Q1 2021.
- In the past 5 years, ENDRA Life Sciences' Gains from Investment Securities registered a high of $3.6 million during Q3 2021, and its lowest value of -$424210.0 during Q4 2019.
- Moreover, its 3-year median value for Gains from Investment Securities was $158187.5 (2019), whereas its average is $432734.0.
- In the last 5 years, ENDRA Life Sciences' Gains from Investment Securities surged by 250417.96% in 2020 and then crashed by 1594.58% in 2021.
- Over the past 3 years, ENDRA Life Sciences' Gains from Investment Securities (Quarter) stood at -$424210.0 in 2019, then increased by 14.17% to -$364113.0 in 2020, then soared by 1080.38% to $3.6 million in 2021.
- Its Gains from Investment Securities stands at $3.6 million for Q3 2021, versus $331520.0 for Q1 2021 and -$364113.0 for Q4 2020.